You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Claims for Patent: 8,129,385


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,129,385
Title:Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Abstract: The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-di- ones useful as anti-HIV agents. The compounds have the formula: ##STR00001## Z.dbd.O; R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 independently are hydrogen, C.sub.1-C.sub.8 alkyl, (C.sub.6-C.sub.14)aryl-(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or optionally substituted lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
Inventor(s): Johns; Brian Alvin (Research Triangle Park, NC), Kawasuji; Takashi (Osaka, JP), Taishi; Teruhiko (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP) GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:11/919,386
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,129,385
Patent Claims: 1. A compound of the formula: ##STR00212## wherein, ring A is ##STR00213## R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 are independently hydrogen, C.sub.1-C.sub.8alkyl, C.sub.6-C.sub.14arylC.sub.1-C.sub.8alkyl, C.sub.6-C.sub.14aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or lower alkyl which is optionally substituted with I to 4 substituents selected from the group consisting of hydroxy, carboxy, halogen, halo lower alkyl, halo lower alkoxy, lower alkyl, lower alkenyl, lower alkynyl. cycloalkyl, cycloalkenyl, lower alkoxy, lower alkenyloxy, lower alkoxycarbonyl, nitro, nitroso, amino, alkylamino, acylamino, aralkylamino, aryl, aralkyl. cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapto, alkylthio, alkylsulfonyl, alkylsulfonylamino, carbamoyl, alkylcarbamoyl, sulfamoyl, acyl, formyloxy. haloformyl, oral, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, azido, ureido, guanidino, phthalimide, oxo, phosphoric acid, lower alkyl which is substituted with phosphoric acid and may be intervened with a heteroatom, aryl substituted with phosphoric acid, aralkyl substituted with phosphoric acid and hydroxy lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sup.X is hydrogen; R.sup.14 is hydrogen; R.sup.3 is hydrogen; m is 1, 2 or 3 and R is halogen.

3. A compound according to claim 1 wherein the pharmaceutically acceptable salt is a sodium salt.

4. A compound of formula (1-7): ##STR00214## wherein: R.sup.a is --CH.sub.3, --CH(CH.sub.3).sub.2, or --CH.sub.2CH.sub.2OCH.sub.3, and (R)m and the phenyl ring to which it is attached is 4-fluorophenyl, 2,4-difluorophenyl or 3-chloro-2-fluorophenyl; or a pharmaceutically acceptable salt thereof.

5. A compound selected from the group consisting of: (3S,9aS)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (3R,9aR)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (4S,9aR)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2R,9aR)-5-Hydroxy-2-methoxymethyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-- 1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aS)-5-Hydroxy-2-methoxymethyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-- 1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aR)-2-Ethyl-5-hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a- ,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2R,9aS)-2-Ethyl-5-hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a- ,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aS)-5-Hydroxy-6,10-dioxo-2-phenyl-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aS)-5-Hydroxy-2-isopropyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-ox- a-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2R,9aR)-5-Hydroxy-2-isopropyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-ox- a-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (3S,9aS)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; (3R,9aR)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; (2R,9aS)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aR)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aR)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; (2R,9aS)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; 5-Hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diazaanthrace- ne-7-carboxylic acid 4-fluorobenzylamide; 5-Hydroxy-3,3-dimethyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-- diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; 5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diza- zaanthracene-7-carboxylic acid 4-fluorobenzylamide; 5-Hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthrac- ene-7-carboxylic acid 2,4-difluoro-benzylamide; 5-Hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthrac- ene-7-carboxylic acid 3-chloro-2-fluoro-benzylamide; enantiomers thereof; diastereomers thereof; mixtures of enantiomers thereof; mixtures of diastereomers thereof; mixtures of enantiomers and diastereomers thereof; and pharmaceutically acceptable salts thereof.

6. A compound selected from the group consisting of (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; an enantiomer thereof; diastereomer thereof; mixtures of enantiomers thereof; mixtures of diastereomers thereof; mixtures of enantiomers and diastereomers thereof; or a pharmaceutically acceptable salt thereof.

7. A compound which is (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide or a pharmaceutically acceptable salt thereof.

8. A compound which is (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic ac id 2,4-difluoro-benzylamide sodium salt.

9. A compound which is (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide.

10. A pharmaceutical composition comprising (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition comprising a compound according to any one of claims 1, 5, 6, 7, 8, 9 or 4, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.